Periodic Reporting for period 1 - IRIS Phase-1 (A revolutionary blood test to easily diagnose and prevent deadly complications of organs and tissue transplants.)
Reporting period: 2019-06-01 to 2019-11-30
Problem: 50% of individuals who get a bone marrow transplant will develop GVHD and 50% of those individuals will die from it. The problem for physicians is that there is no way for them to identify a patient developing GVHD until the patient demonstrates observable symptoms, which only occur at the very end of the disorder when many treatments are no longer effective. Even then, a biopsy is required for a diagnosis to be rendered. The biopsy is painful, time consuming (takes up to 24 to 48 hours) and not reliable. For almost 3 decades now observable symptoms and a biopsy has been the standard of care for diagnosing GVHD and 1 in every 4 bone marrow transplant patients are dying.
Marx Biotechnology’s diagnostic kit will save lives, reduce costs, and improve patient care by allowing doctors to make quick, accurate and efficient decisions on how best to manage and treat their patients. It will provide loved ones and the patient with peace of mind through knowing the patient’s condition quickly and accurately, and by reducing the financial burden to the patient and his or her loved ones.
Marx Biotechnology’s diagnostic kit will save lives, reduce costs, and improve patient care by allowing doctors to make quick, accurate and efficient decisions on how best to manage and treat their patients. It will provide loved ones and the patient with peace of mind through knowing the patient’s condition quickly and accurately, and by reducing the financial burden to the patient and his or her loved ones.
We have performed a feasibility study to analyse the technical, clinical, commercial and financial feasibility of our disruptive idea. We have confirmed and we have defined the Go TO Market Strategy we must follow to successfully introduce the product in the market.
Potential impact: Our goal is for the blood of Marx Biotechnology to become the stand of care in the industry. That our blood test will be the gold standard for monitoring patients for the onset and progression of GVHD. This will have a huge socioeconomic impact minimizing treatments and hospitalization saving both lives and money. Marx Biotechnology’s diagnostic kit will allow doctors to make quick, accurate and efficient decisions on how best to manage and treat their patients. It will provide loved ones and the patient with peace of mind through knowing the patient’s condition quickly and accurately, and by reducing the financial burden to the patient and their loved ones.